Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 3:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 457 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Seizures, Epileptic Clear all
Completed No phase listed Observational Accepts healthy volunteers

Role of Hormones in Susceptibility to Seizures in Women With Epilepsy

NCT00044252
View directory record Official record
Conditions
Epilepsy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 2, 2026, 3:08 AM EDT
Completed Phase 3 Interventional Results available

Trial to Assess Long-term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-onset Seizures

NCT00530855
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years to 70 Years
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
77
States / cities
Alabaster, Alabama • Birmingham, Alabama • Northport, Alabama + 66 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 2, 2026, 3:08 AM EDT
Completed No phase listed Observational

Evaluating the Role of Inflammation in Neonatal Epileptogenesis

NCT04259125
View directory record Official record
Conditions
Neonatal Seizure, Epilepsy, Seizures, Inflammatory Response
Interventions
Blood draw, Survey
Diagnostic Test · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Day to 4 Days
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
4
States / cities
Oakland, California • San Francisco, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 2, 2026, 3:08 AM EDT
Active, not recruiting Not applicable Interventional

A Pilot Study: Focused Ultrasound Thalamotomy for the Prevention of Secondary Generalization in Focal Onset Epilepsy

NCT03417297
View directory record Official record
Conditions
Partial Seizures With Secondary Generalization, Focal Epilepsy With Secondary Generalization
Interventions
High Intensity Focused Ultrasound
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 2, 2026, 3:08 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Determination of Absorption and Elimination of Lamotrigine-XR

NCT00789113
View directory record Official record
Conditions
Epilepsy, Seizures, Bipolar Disorder, Bipolar Depression
Interventions
Extended Release Lamotrigine
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
65 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 2, 2026, 3:08 AM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

NCT02224690
View directory record Official record
Conditions
Epilepsy, Lennox-Gastaut Syndrome
Interventions
GWP42003-P 20 mg/kg/day Dose, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 55 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
17
States / cities
Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 2, 2026, 3:08 AM EDT
Completed Phase 2 Interventional

Transcranial Magnetic Stimulation to Treat Epilepsy

NCT00048490
View directory record Official record
Conditions
Epilepsy
Interventions
transcranial magnetic stimulation (TMS)
Device
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 2, 2026, 3:08 AM EDT
Terminated Not applicable Interventional

Pre-oxygenation and Measures of Gas Exchanges During Seizures in the Epilepsy Monitoring Unit

NCT02241798
View directory record Official record
Conditions
Epilepsy
Interventions
oxygen
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 2, 2026, 3:08 AM EDT
Completed Phase 3 Interventional Results available

Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures

NCT00152516
View directory record Official record
Conditions
Epilepsy, Partial
Interventions
levetiracetam (LEV)
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
1 Month to 16 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
38
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Oct 2, 2026, 3:08 AM EDT
Completed Phase 3 Interventional Results available

Eslicarbazepine Acetate Monotherapy Long Term Study

NCT00910247
View directory record Official record
Conditions
Epilepsy
Interventions
Eslicarbazepine acetate
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
96
States / cities
Northport, Alabama • Phoenix, Arizona • Sun City, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 2, 2026, 3:08 AM EDT
Completed No phase listed Observational

Transcranial Magnetic Stimulation for the Treatment of Poorly Controlled Partial Epilepsy

NCT00001666
View directory record Official record
Conditions
Partial Epilepsy, Seizures
Interventions
Cadwell High-Speed Magnetoelectric Stimulator, Magpro High-Speed Magnetoelectric Stimulator
Device
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 2, 2026, 3:08 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.

NCT00319501
View directory record Official record
Conditions
Seizures, Epilepsies, Partial, Epilepsy, Complex Partial, Epilepsy, Generalized, Epilepsy
Interventions
Placebo, Vanquix Auto-Injector (Diazepam Injection)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
86
States / cities
Northport, Alabama • Little Rock, Arkansas • Irvine, California + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 2, 2026, 3:08 AM EDT
Completed Phase 4 Interventional Results available

Treatments for Psychogenic Nonepileptic Seizures (NES)

NCT00159965
View directory record Official record
Conditions
Convulsion, Non-Epileptic, Conversion Disorder, Depression, Stress Disorders, Post-Traumatic
Interventions
sertraline, placebo
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 95 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Oct 2, 2026, 3:08 AM EDT
Completed No phase listed Observational

Effect of Antiseizure Medication on Hormone Levels and Sexual Function in Men With Epilepsy

NCT00179426
View directory record Official record
Conditions
Seizure Disorder, Epilepsy
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 2, 2026, 3:08 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.

NCT05064878
View directory record Official record
Conditions
CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm, Refractory Seizures
Interventions
Fenfluramine, Placebo
Drug
Lead sponsor
Zogenix, Inc.
Industry
Eligibility
1 Year to 35 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 2, 2026, 3:08 AM EDT
Not yet recruiting Not applicable Interventional

Lily's Grace Temporal Interference

NCT07520955
View directory record Official record
Conditions
Epilepsy
Interventions
TES-TI, Sham Stimulation, Structural and Functional MRI
Device · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 2, 2026, 3:08 AM EDT
Enrolling by invitation No phase listed Observational

Study of Direct Brain Recording and Stimulation for Memory Enhancement

NCT04095026
View directory record Official record
Conditions
Epilepsy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 2, 2026, 3:08 AM EDT
Not listed Not applicable Interventional

Forecasting Seizures Using Intelligent Wearable Technology for Health Tracking

NCT06275685
View directory record Official record
Conditions
Epilepsy; Seizure
Interventions
SeizureWise algorithm, Multi-day Visualizations
Device
Lead sponsor
Empatica, Inc.
Industry
Eligibility
6 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 2, 2026, 3:08 AM EDT
Recruiting Phase 2 Interventional

A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures

NCT07219407
View directory record Official record
Conditions
Focal Epilepsy, Epilepsy, Refractory Focal Epilepsy, Seizure, Focal Seizure, Focal Onset Seizure
Interventions
RAP-219
Drug
Lead sponsor
Rapport Therapeutics Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Boise, Idaho • Rochester, Minnesota • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 2, 2026, 3:08 AM EDT
Completed Phase 2 Interventional Results available

A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601

NCT01002820
View directory record Official record
Conditions
Epilepsy, Complex Partial
Interventions
ganaxolone
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
7
States / cities
Los Angeles, California • Lexington, Kentucky • Albany, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Oct 2, 2026, 3:08 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Melatonin and Epilepsy

NCT00965575
View directory record Official record
Conditions
Epilepsy
Interventions
Melatonin, Placebos
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 11 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2020 · Synced Oct 2, 2026, 3:08 AM EDT
Enrolling by invitation No phase listed Observational

SLC13A5 Deficiency Natural History Study - Remote Only

NCT04681781
View directory record Official record
Conditions
Citrate Transporter Deficiency, Epilepsy, Rare Diseases, Movement Disorders, Genetic Disorder, SLC13A5 Deficiency, EIEE25, Kohlschutter-Tonz Syndrome (non-ROGDI), 17p13.1 Deletions Confined to SLC13A5 Gene, Citrate Transporter Disorder
Interventions
Not listed
Lead sponsor
TESS Research Foundation
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 2, 2026, 3:08 AM EDT
Completed Phase 2 Interventional Results available

Double Blind, Crossover Study of Fish Oil [EPA and DHA] for Intractable Partial Seizures

NCT00871377
View directory record Official record
Conditions
Epilepsy
Interventions
Placebo, High Dose Fish Oil, Low Dose Fish Oil
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2014 · Synced Oct 2, 2026, 3:08 AM EDT
Completed Phase 2 Interventional Results available

A Multicenter, Open-Label Study To Investigate The Safety And Pharmacokinetics Of Lacosamide In Children With Partial Seizures

NCT00938431
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
1 Month to 17 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
14
States / cities
Sacramento, California • Washington D.C., District of Columbia • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 2, 2026, 3:08 AM EDT